Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shonan iPark Commences Full-Fledged Operations in South Korea
iPark Institute, an operator of Shonan iPark, formally known as Shonan Health Innovation Park, said on July 12 that its business operations in South Korea are now in full swing. Starting from late June, the institute dispatched staff members to…
To read the full story
Related Article
- Shonan iPark to Drive Japan Approval of New Drugs from Korean Biotechs
February 26, 2025
- Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
- 8 South Korean Biotechs Now Housed at Shonan iPark
September 30, 2024
- Shonan iPark Launches Local Post in South Korea
March 19, 2024
- iPark Institute Inks Collaboration Pact with South Korean Government
November 14, 2023
- Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…